US · Healthcare · Biotechnology
EPS came in at -0.91 against a street estimate of -1.01 — a beat of 9.9%.
Analysts rate Beam Therapeutics Inc a buy (14 buy, 3 hold, 0 sell out of 17) with an average price target of $52.31.
| Fund | Stake |
|---|---|
| FMR Inc | 12.10% |
| ARK Investment Management LLC | 11.79% |
| Farallon Capital Management, L.L.C. | 9.85% |
| BlackRock Inc | 8.25% |
| State Street Corp | 5.54% |
| Vanguard Portfolio Management, LLC | 4.44% |
| ARCH VENTURE CORP | 4.41% |
| Vanguard Capital Management, LLC | 4.25% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-08 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-17 |
| Current report · Q1 2026 | 2026-03-05 |
| Annual report FY2025 | 2026-02-24 |
| Results announced · Q1 2026 | 2026-02-24 |
| Quarterly report · Q3 2025 | 2025-11-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Beam Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.